[go: up one dir, main page]

ES2117390T3 - Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen. - Google Patents

Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.

Info

Publication number
ES2117390T3
ES2117390T3 ES95903298T ES95903298T ES2117390T3 ES 2117390 T3 ES2117390 T3 ES 2117390T3 ES 95903298 T ES95903298 T ES 95903298T ES 95903298 T ES95903298 T ES 95903298T ES 2117390 T3 ES2117390 T3 ES 2117390T3
Authority
ES
Spain
Prior art keywords
salts
fatty acid
pharmaceutical formulations
formulations containing
polyinsaturated fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95903298T
Other languages
English (en)
Inventor
Tiberio Bruzzese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prospa NV
Original Assignee
Prospa NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prospa NV filed Critical Prospa NV
Application granted granted Critical
Publication of ES2117390T3 publication Critical patent/ES2117390T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SALES DE ACIDO 4,7,10,13,16,19 - CIS - DOCOSAHEXAENOICO (DHA) CON AMINOACIDOS BASICOS, EN PARTICULAR ARGININA Y LISINA, TIENEN CARACTERISTICAS TERAPEUTICAS Y TECNOLOGICAS FAVORABLES (SOLUBILIDAD EN AGUA) COMPARADAS CON EL ACIDO DE INICIO.
ES95903298T 1993-12-14 1994-11-28 Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen. Expired - Lifetime ES2117390T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93MI002612A IT1264987B1 (it) 1993-12-14 1993-12-14 Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono

Publications (1)

Publication Number Publication Date
ES2117390T3 true ES2117390T3 (es) 1998-08-01

Family

ID=11367322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95903298T Expired - Lifetime ES2117390T3 (es) 1993-12-14 1994-11-28 Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.

Country Status (8)

Country Link
US (1) US5750572A (es)
EP (1) EP0734373B1 (es)
JP (1) JPH09508619A (es)
AU (1) AU1241295A (es)
DE (1) DE69409969T2 (es)
ES (1) ES2117390T3 (es)
IT (1) IT1264987B1 (es)
WO (1) WO1995016661A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
AUPM906594A0 (en) * 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
FR2781371B1 (fr) * 1998-07-21 2001-04-27 Oreal Composition cosmetique aqueuse transparente a une seule phase
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
ATE556706T1 (de) * 2001-03-23 2012-05-15 Luitpold Pharm Inc Fettalkohol-arzneimittel-konjugate
JP2005500988A (ja) 2001-03-23 2005-01-13 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪族アミン薬物複合体
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US8052992B2 (en) * 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
HU227588B1 (hu) * 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
EP2224930B1 (en) 2008-01-04 2016-06-15 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
US20110237670A1 (en) 2008-12-12 2011-09-29 Daniel Klamer Improvement of normal cognitive function
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
CN107074884A (zh) * 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
ES2776393T3 (es) * 2014-12-23 2020-07-30 Evonik Operations Gmbh Procedimiento para incrementar la estabilidad de una composición que comprende ácidos grasos omega-6 poliinsaturados
RU2706202C2 (ru) * 2014-12-23 2019-11-15 Эвоник Дегусса Гмбх Способ повышения устойчивости композиции, содержащей омега-3 полиненасыщенные жирные кислоты
FR3031451B1 (fr) * 2015-01-13 2018-03-23 Greentech Sel d'un triglyceride, preparation et utilisations
ES2956766T3 (es) 2016-05-25 2023-12-27 Evonik Operations Gmbh Comprimidos con alto contenido en principios activos de sales de ácidos grasos omega-3 y aminoácidos
EP3248467A1 (de) 2016-05-25 2017-11-29 Evonik Technochemie GmbH Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze
CN109562186B (zh) 2016-06-03 2022-09-13 西蒂斯制药有限责任公司 与专门促消退介质的盐有关的组合物和方法
WO2019008101A1 (en) 2017-07-06 2019-01-10 Evonik Technochemie Gmbh ENTERICALLY COATED SOLID DOSAGE FORM COMPRISING AMINO ACIDS SALTS OF OMEGA-3 FATTY ACIDS
AU2018317802B2 (en) 2017-08-15 2024-04-04 Evonik Operations Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
KR102172036B1 (ko) * 2017-11-08 2020-10-30 주식회사 오스테온 악취 억제형 불포화오일 및 아르기닌 함유 조성물의 제조 방법
WO2019093708A1 (ko) * 2017-11-08 2019-05-16 김승수 악취 억제형 불포화오일 및 아르기닌 함유 조성물의 제조 방법
WO2020109472A1 (en) * 2018-11-30 2020-06-04 Evonik Operations Gmbh Preparation comprising a dispersion of phospholipids and fatty acid salts
US20220233487A1 (en) 2019-05-06 2022-07-28 Evonik Operations Gmbh Preparation for use in weight management comprising omega-3 fatty acid salts and basic amino acids
WO2020234221A1 (en) * 2019-05-23 2020-11-26 Evonik Operations Gmbh Prebiotic compositions
EP4009961A1 (en) 2019-08-08 2022-06-15 Evonik Operations GmbH Solubility enhancement of poorly soluble actives
EP3804699A1 (en) 2019-10-10 2021-04-14 Evonik Operations GmbH Method of preparing a solid dosage form and a binder
EP4009960A1 (en) 2019-08-08 2022-06-15 Evonik Operations GmbH Method of preparing a solid dosage form and a binder
AU2020324553A1 (en) 2019-08-08 2022-03-24 Evonik Operations Gmbh Method of preparing a solid dosage form and a lubricant
EP4009956A1 (en) 2019-08-08 2022-06-15 Evonik Operations GmbH Down streaming process for the production of polyunsaturated fatty acid salts
WO2021151199A1 (en) * 2020-01-30 2021-08-05 Silicycle Inc. Process for preparing a solid form of basic amino acid salts of polyunsaturated fatty acids
EP4125438A1 (en) 2020-04-01 2023-02-08 Evonik Operations GmbH Preparation for use as antioxidant
US20230037453A1 (en) 2020-04-01 2023-02-09 Evonik Operations Gmbh Preparation for use as vasorelaxant
DE102022003441A1 (de) 2022-09-17 2024-03-28 Jutta Ibrahim Nahrungsergänzungsmittel Omega3 und essentielle Aminosäure(n)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7405325A (es) * 1973-04-25 1974-10-29
HU209973B (en) * 1988-03-09 1995-01-30 Biorex Kutato Fejlesztoe Kft Process for production of antiviral and immunstimular pharmaceutical composition
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production

Also Published As

Publication number Publication date
DE69409969T2 (de) 1998-12-10
ITMI932612A0 (it) 1993-12-14
US5750572A (en) 1998-05-12
ITMI932612A1 (it) 1995-06-14
IT1264987B1 (it) 1996-10-17
EP0734373B1 (en) 1998-04-29
AU1241295A (en) 1995-07-03
JPH09508619A (ja) 1997-09-02
WO1995016661A1 (en) 1995-06-22
EP0734373A1 (en) 1996-10-02
DE69409969D1 (de) 1998-06-04

Similar Documents

Publication Publication Date Title
ES2117390T3 (es) Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.
NO940277L (no) Triglycerider og blandinger av slike
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
ES2195175T3 (es) Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico.
DE3875425D1 (de) Vasokinetisch wirkende polyungesaettigte saeuren und sie enthaltende pharmazeutische oder kosmetische zubereitungen.
ES2099022B1 (es) Composiciones farmaceuticas que contienen las sales de acido s(+)-2-(4-isobutilfenil) propionico con aminoacidos basicos.
NO940288L (no) Formuleringer inneholdende umettede fettsyrer
FI970298A0 (fi) DHA:n käyttö farmaseuttisena koostumuksena
ES2166166T3 (es) Analogos de peptido lh-rh, sus usos y composiciones farmaceuticas que los contienen.
ES2149253T3 (es) Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.
FI863976A0 (fi) Terapeutisk komposition.
DE3862337D1 (de) Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten.
ES2093395T3 (es) Esteres de acil carnitinas con alcoholes alifaticos de cadena larga y composiciones farmaceuticas que los contienen con actividad antibacteriana.
GB8812653D0 (en) Pharmaceutical composition based on high concentration esters of docosahexaenoic acid
ES2196187T3 (es) Conjugados peptidicos derivados de las hormonas timicas, su utilizacion a titulo de medicamento y composiciones que los contienen.
ES2069915T3 (es) Dicarbonatos y uretanos de los acidos 4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracenocarboxilicos que tienen actividades terapeuticas.
ATE191341T1 (de) Tabletten mit thioctsäure bestimmter korngrösse
ES2062529T3 (es) Uso de alcoholes alifaticos, de c-20 a c-26, para la realizacion de un medicamento destinado al tratamiento de infecciones virales.
ES2084348T3 (es) N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares.
ES2082390T3 (es) Acido gamma-linolenico para la preparacion de un medicamento para impedir la reoclusion de las arterias.
ES2163450T3 (es) Utilizacion de benzidamina en el tratamiento de estados patologicos causados por tnf.
DK138191A (da) Salicylsyreholdigt middel til behandling af afskallende hudlidelser
DE69423623D1 (de) Aminosäureergänzung
SE8504191L (sv) Acetyldikarnitin
Wenderoth Aspects of the new eicosanoid-research.).

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 734373

Country of ref document: ES